Spero CEO Ankit Mahadevia to become chairman, Sath Shukla to succeed

Spero Therapeutics announced that Satyavrat “Sath” Shukla, Spero’s current CFO and Treasurer, will serve as Spero’s President and CEO, and as a member of the Board of Directors, effective August 1, 2023. Shukla will succeed Spero’s current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023. The current Chairman of the Board, Milind Deshpande, Ph.D., will remain on the Board as an independent director, and current Board member, Patrick Vink, MD., will be appointed Lead Independent Director. Spero has now launched a search for the next CFO to succeed Mr. Shukla. Until this search is completed, the Board has appointed Stephen J. DiPalma as Interim CFO and Treasurer, effective August 1, 2023.